Bing-Fei Xu
YOU?
Author Swipe
Osimertinib with or without savolitinib as first-line treatment for MET-aberrant, EGFR-mutant NSCLC: randomized phase 2 trial (FLOWERS) Open
To investigate the efficacy and safety of osimertinib plus savolitinib for patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations and de novo MET aberrations, we conducted a randomi…
View article: Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial
Efficacy, safety and dose selection of AZD3759 in patients with untreated EGFR-mutated non-small-cell lung cancer and central nervous system metastases in China (CTONG1702-Arm 8): a multi-center, single-arm, phase 2 trial Open
Chinese Thoracic Oncology Group (CTONG).
Ferroptosis: A Novel Anti-tumor Action for Cisplatin Open
Ferroptosis had great potential to become a new approach in anti-tumor therapies and make up for some classic drugs, which open up a new way for their utility in clinic.
Additional file 1: of HN1 contributes to migration, invasion, and tumorigenesis of breast cancer by enhancing MYC activity Open
Fresh human tissue samples including 12 breast cancer tissues and 4 normal mammary tissues. (XLSX 17.3 kb)